The US Radio Pharmaceutical Market is emerging as an important part of the US nuclear medicine sector, supported by demand for accurate imaging and more targeted treatment options. The market is projected to grow from USD 1.5 billion in 2024 to USD 4.0 billion by 2035, representing a 9.33% CAGR from 2025 to 2035.

Radiopharmaceutical development is becoming more sophisticated through advances in imaging systems, radiochemistry, and targeted compounds. PET and SPECT remain important technologies, while artificial intelligence and personalized medicine are creating new ways to improve image interpretation and tailor treatments to individual patients.

Major uses include diagnosis, therapy, and research across areas such as oncology, cardiology, and neurology. Diagnosis currently leads the application landscape, while therapeutic radiopharmaceuticals are expanding as researchers and healthcare providers explore more targeted options for cancer and other serious diseases.

Hospitals are the largest end users because of their extensive diagnostic and therapeutic capabilities. Imaging centers also play a significant role, while research institutions are becoming a growing source of demand as investment increases in the discovery and testing of new radiopharmaceutical products.

Over the coming years, the market could benefit from targeted radiopharmaceutical therapies, precision oncology, advanced diagnostic agents, and stronger radiopharmacy networks. Continued research and regulatory development should create additional opportunities for innovative products across diagnosis and treatment.